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Despite a more advanced stage of disease at presentation, a better response to radioiodine (RAI) therapy and a reduced overall
mortality have been reported in pediatric differentiated thyroid cancer (DTC) in comparison to adult DTC. Few studies suggested
that the better response to RAI therapy in pediatric patients might be associated with an increased expression of NIS. However, a
marked heterogeneity within the pediatric group has been recognized. Children (<10 years old) usually present a more aggressive
disease than adolescents (≥10–18 years old). By analyzing the expression of thyroid-specific genes in 38 sporadic pediatric tumors, we
show that the expression of NIS, PDS, and TSHR was lower in children than adolescents (𝑃 < 0.05). A linear regression confirmed
the association between NIS expression and age. Most significantly, NIS was expressed at similar levels in DTC from children and
adults, whereas PDS and TSHR expression was even lower in DTC from children, compared to adolescents and adults. Our data
suggest that biological behaviors of DTC in adolescents might differ from those in children and adults. Therefore, the premise that
the expression of thyroid-specific genes is higher in tumors from pediatric patients than in adults is not entirely true and might be
too oversimplified.
1. Introduction
Thyroid cancer is the fastest increasing cancer worldwide [1].
Although the highest incidence rates are observed in the fifth
decade and it is rare in the younger population, the incidence
of thyroid cancer is also increasing in children (<10 years old)
and adolescents (≥10–18 years old) [2, 3]. Thyroid cancer is
the 2nd most prevalent cancer in females aged 15 to 19 years
[4]. Similar to adults (>18 years old), differentiated thyroid
carcinomas (DTC) are the most common malignancy, with
nearly 75–90% being papillary thyroid carcinoma (PTC) and
the remainder follicular thyroid carcinoma (FTC) [2].
Previous studies reported significant differences in the
clinical presentation and outcomes of DTC in pediatric
patients (≤18 years old) compared to adults [5, 6]. Despite a
more advanced stage of disease at presentation and higher
rates of recurrences than adults, the overall mortality is
lower [7–9]. Unlike adults, pediatric patients have a higher
prevalence of pulmonarymetastases, which almost always are
functional [10–12]. This may explain why pediatric patients
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Table 1: Summary of the clinicopathological features of pediatric thyroid carcinoma.
Total Patients <10 yr old Patients ≥10–18 yr old
𝑃 value
𝑛 = 38 𝑛 = 13 𝑛 = 25
Mean age ± SD 11.84 (±4.4) 6.76 (±1.92) 14.48 (±2.63) <0.0001
Gender
Female 29 8 (62%) 21 (84%) 0.2262
Male 9 5 (38%) 3 (16%)
Tumor size (cm) mean ± SD 2.65 (±1.48) 2.28 (±1.49) 2.83 (±1.48) 0.2383
Risk factors
Family history 2 1 (8%) 1 (4%) 1.00
Exposure to radiation 4 0 4 (16%) 0.2779
Extrathyroidal extension 16 9 (69%) 7 (28%) 0.0448
Multifocal disease 17 4 (31%) 13 (52%) 0.3068
LN metastases 28 11 (85%) 17 (68%) 0.4413
Distant metastases 10 6 (46%) 4 (16%) 0.0620
with DTC have better responsiveness to radioiodine (RAI)
therapy than the adults [10, 11]. In fact, some studies have
shown that most pediatric DTC patients had a complete
remission after RAI therapy, mainly those adolescents with
iodine-avid pulmonary metastases [12–14].
The better response to RAI therapy in pediatric patients
might infer greater degree of differentiation and higher
expression of proteins involved in iodine uptake and
metabolism. The transport of iodide into thyroid follicular
cells is a result of an active transport mechanism mediated
by the sodium iodide symporter (NIS) protein, an integral
plasma membrane glycoprotein located at the basolateral
membrane of thyroid follicular cells [15]. Following active
transport across the membrane, iodide is translocated across
the apical membrane by pendrin (PDS) and organified by
thyroid peroxidase (TPO). These actions are reliant on the
thyroid-stimulating hormone (TSH), which interacts with
the TSH receptor (TSHR) at the basolateral membrane of
follicular cells [15].
Therefore, there is a strong need to investigate whether
the expression of proteins involved in iodine uptake and
metabolism differs between pediatric and adult populations.
In fact, it has been suggested that NIS expression was
associated with lower risk of recurrence of pediatric thyroid
carcinomas [16, 17]. Additionally, the dose of 131I required
to achieve remission was directly related to the levels of NIS
expression, being higher in those patients with undetectable
NIS expression [17, 18].The expression of PDSwas also found
diminished in pediatric patients [5].
Nevertheless, amarked heterogeneitywithin the pediatric
group has been reported. Some earlier studies suggested
that children present with more aggressive local disease and
are more likely to have lymph node metastases at diagnosis
and, probably, more prone to develop subsequent distant
metastases than adolescents [2, 7, 8, 11, 19, 20]. It has also been
reported that children experience recurrencemore frequently
and earlier than adolescents [21, 22].
Therefore, there is a strong need for studies in both
children and adolescents. Although efforts have been made,
the role of RAI therapy in pediatric patients has been
mainly assessed in adolescents. Most studies used a very
small number of children or prepubertal patients [10, 23],
which makes it difficult to stratify pediatric patients into
age groups or pubertal status and to test the hypothesis that
the expression of genes associated with iodine uptake and
metabolism might be higher in adolescents than in children.
As most studies are retrospective or included a small number
of children, it still remains unclear whether age influences the
behavior of DTC within pediatric population [24].
To bridge some of the existing gap, this study investigated
the expression of NIS, PDS, TPO, TSHR, and thyroglobulin
(TG) in a cohort of pediatric patients and correlated with
clinicopathological features. To further explore a possible
association of the expression of thyroid-specific genes with
age, the expression analysis was performed in pediatric
patients stratified into two age groups (<10 and ≥10–18 years).
As our analysis suggests an impact of age on gene expression,
the genes whose expression pattern differed between children
and adolescents were further compared with their expression
in DTC from adults.
2. Materials and Methods
2.1. Thyroid Samples. The series consists of 47 formalin-fixed
paraffin-embedded (FFPE) sections from 38 primary tumors
from pediatric patients who underwent thyroid surgery at
Hospital Sa˜o Paulo (Universidade Federal de Sa˜o Paulo) and
Hospital da Santa Casa de Sa˜o Paulo between the years 1993
and 2012. The pediatric cohort included 35 PTCs, 3 FTCs,
and 9-matched normal thyroid tissues. All samples were
reviewed by two pathologists (RD and MTSA). The clinical
and pathological features are summarized in Table 1.
As recommended by theATAguidelines for childrenwith
thyroid nodules and DTC, all of the pediatric patients were
≤18 years of age at the time of diagnosis [24]. The pediatric
cases were further separated into two age groups: children
(<10 years old) and adolescents (≥10–18 years old). Because
information about pubertal development was not available
for all of the patients, the age of 10 was used as the cut-off
International Journal of Endocrinology 3
Table 2: Summary of the clinicopathological features of pediatric
and adult thyroid carcinoma.
Pediatric Adult
𝑃 value
𝑛 = 38 𝑛 = 115
Mean age ± SD 11.84 (4–18 ys) 45.29 (20–76)
Gender
Female 29 (76%) 96 (83%) 0.3387
Male 9 (24%) 19 (17%)
Extrathyroidal extension 16 (42%) 39 (34%) 0.5596
Multifocal disease 17 (45%) 56 (49%) 0.7082
LN metastases 28 (74%) 48 (42%) 0.0007
Distant metastases 10 (26%) 4 (3%) 0.0002
point. This cut-off point was recommended by the World
HealthOrganization (WHO) andused to determine the effect
of age on time to recurrence and mortality rates in pediatric
DTC [21, 22].
The adult cohort included 115 PTC and 7 adjacent nor-
mal thyroid tissues obtained from patients who underwent
thyroid surgery from 2000 through 2007 at Hospital Sa˜o
Paulo (Universidade Federal de Sa˜o Paulo) and Hospital
das Cl´ınicas de Sa˜o Paulo (Universidade de Sa˜o Paulo). The
clinical and pathological features are summarized in Table 2.
The control groups (normal thyroid tissues) included
only those samples from the contralateral nodule of patients
with unilateral DTC (i.e., no evidence of either benign or
malignant thyroid disease in the contralateral nodule). The
study was conducted under the approval of the Review
Boards and Research Ethical Committees of the affiliated
institutions.
2.2. RNA Isolation and cDNA Synthesis. Total RNA was
isolated from 10𝜇mthick FFPE sections using theRecoverAll
Total Nucleic Acid isolation kit (Ambion Inc., Austin, TX).
Total RNA (500 ng) was treated with DNAse and reverse-
transcribed into cDNA with oligo-dT12–18 (50 𝜇M) and ran-
dom hexamers (50 ng) using a Superscript III transcriptase
kit (Invitrogen Corp., Carlsbad, CA).
2.3. Expression of Thyroid-Specific Genes in Thyroid Samples
by Quantitative RT-PCR. The thyroid samples were screened
for the expression of target genes (NIS, TG, TPO, PDS, and
TSHR) and the reference gene (RPS8) by quantitative RT-
PCR (qRT-PCR), as previously described [25, 26]. Briefly, an
aliquot of cDNAwas used in a 12 𝜇L PCR reaction containing
SYBR Green PCR Master Mix (PE Applied Biosystems)
and 3 pmol of each specific primer. The PCR reaction was
subjected to 40 cycles at 95∘C for 15 seconds and 60∘C for 1
minute.TheqPCR reactionswere performed in triplicate, and
the Ct was obtained and averaged (SD < 0.85). The relative
expression (RE) was calculated according to the comparative
ΔΔCt method. Normal thyroid samples were used as the
control group. The choice to use the RPS8 as the reference
gene is based on previous analyses from our group that
identified this gene as the best suitable reference gene for
thyroid tissues [27]. The PCR primers are summarized in
Supplementary Table 1 (see SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2016/1956740).
2.4. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA,
USA) and R 3.1.3. (R software). Mann-Whitney 𝑈 test or
Student’s 𝑡-test was used to compare the continuous variables,
and Fisher’s exact test was used for dichotomous variables.
The associations were tested using discriminant analysis or
linear regression when applicable. The results with 𝑃 < 0.05
were considered to be statistically significant.
3. Results
3.1. Clinical and Pathological Features of Pediatric Patients.
The mean age at diagnosis was 11.84 years (range, 4 to 18
years). The median age of the pediatric control group was
11.7 years (range from 7 to 17 years) and, therefore, similar
to that observed in pediatric thyroid cancer group. The
female to male ratio was 29 : 9, with female predominance
mainly in the adolescent group. The pathological findings
included multifocality in 17 (45%), extrathyroidal extension
in 16 (42%), lymph node metastases at diagnosis in 28 (74%),
and lung metastasis in 10 (26%) patients. Two of the patients
had a family history for PTC, and four cases had a history
of previous radiation exposure during childhood to treat
another cancer (Table 1). When compared to adults, higher
rate of cervical metastases was identified in pediatric patients
compared to adults (74% versus 42%; 𝑃 = 0.0007), as well
as pulmonary metastases (26% versus 3%; 𝑃 < 0.0002)
(Table 2).
To better understand clinical, pathological and expression
differences between children and adolescents, the patients
were classified into two age groups.Thirteen cases (34%)were
<10 years of age, and 25 cases (66%) were ≥10–18 years of
age. An increased prevalence of extrathyroidal extension was
observed among the children compared to the adolescents
(69% versus 28%; 𝑃 = 0.0448). Children also had a higher
tendency to develop lung metastasis than adolescents (46%
versus 16%; 𝑃 = 0.0620) (Table 1).
3.2. Expression ofThyroid-Specific Genes and Correlation with
Clinical and Pathological Features and Molecular Status. The
expression of TG, NIS, PDS, and TPO was significantly lower
in pediatric thyroid carcinomas compared to the normal thy-
roid tissue (Figure 1;𝑃 < 0.05). Importantly, the expression of
NIS, PDS, and TSHR was consistently lower in children than
in adolescents (Figure 2; 𝑃 < 0.05). Considering the clinical
and pathological features associatedwith poor prognosis,NIS
and TSHRmRNA expression was significantly lower in those
tumors with extrathyroidal extension. Besides, NIS mRNA
expression was notably lower in those tumors from patients
with lung metastases (Figure 3). Multiple linear regression
analysis confirmed the association between age and NIS
expression, regardless of the other clinicopathological fea-
tures.
As NIS, PDS, and TSHR were differentially expressed
between children and adolescent groups, we further com-
pared those changes to the changes we observed in adult
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Figure 1: Relative expression (RE) of thyroid-specific genes in differentiated thyroid carcinomas (DTC) (𝑛 = 38) and normal thyroid tissues
(𝑛 = 9) from pediatric patients. The graphics shows the mean value (±SD) of log-transformed data. 𝑃 < 0.05 were considered statistically
significant.
population [25, 26]. We observed here that children and
adults in have similar NIS mRNA expression. Remarkably,
NIS expression was significantly higher in tumors from
adolescents than tumors from adults (𝑃 < 0.05) (Figure 4).
The range of TSHR and PDS expression in children was
considerably lower as compared to adults (𝑃 < 0.05)
(Figure 4).
Seeing that adult population is characterized by a wide
age range (20–70 years) and that older patients have more
aggressive disease, we separated younger adults (<45 year old)
from older adults and evaluated the expression of NIS, PDS,
and TSHR in these groups. However, the expression of these
genes did not differ between these two age groups (data not
presented).
4. Discussion
Previous studies reported significant differences in the clin-
ical presentation and outcomes of DTC among pediatric
patients when compared to adults. Pediatric patients have
larger tumor size, have more extensive local disease, are more
likely to present with lymph node and distant metastases,
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Figure 2: Relative expression (RE) of thyroid-specific genes in pediatric thyroid carcinomas classified according age: children (𝑛 = 13; <10
years old) or adolescents (𝑛 = 25; ≥10 years old). The graphics shows the mean (±SD). Data was log-transformed before analysis. 𝑃 < 0.05
were considered statistically significant.
and have a higher frequency of functional metastases. The
discrepancy between more aggressive disease at diagnosis
and higher recurrence rates but amore favorable progression-
free survival is quite remarkable [11]. It is still not clear
whether these differences observed between pediatric and
adult DTC lie in the existence of distinct gene expression
and/or mutational profile. It has been suggested that the
rare progression to less-differentiated tumor and the better
response to RAI therapy are due to higher expression of key
genes involved in thyroid function, including NIS [11].
Another intriguing point is the heterogeneity reported
within pediatric group. As most studies included a very small
number of children, it is still unclear whether younger age
is associated with an increased risk for extensive disease.
Studies, in which the number of children is roughly 25% of
the pediatric cohort, showed that young age is correlated with
a higher risk for extensive disease or recurrence [8, 19, 20].
In this work, we identified a significant decrease in TG,
NIS, PDS, and TPO expression in pediatric DTC compared
to paired-normal thyroid tissues. Moreover, the age-related
6 International Journal of Endocrinology
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Figure 3: Relative expression (RE) of TSHR andNIS in pediatric thyroid carcinomas classified according to the presence (𝑛 = 22) or absence
(𝑛 = 16) of extrathyroidal (ET) extension; and RE expression of NIS in patients classified according to the presence (𝑛 = 10) or absence
(𝑛 = 28) of distant metastasis. The graphics shows the mean value (±SD) of log-transformed data. 𝑃 < 0.05 were considered statistically
significant.
analysis revealed that the expression of NIS, PDS, and TSHR
was significantly lower in children than in adolescents.
Remarkably, children had a higher rate of extrathyroidal
extension and a trend towards a higher prevalence of distant
metastases than adolescents.
Although one study previously investigated the expres-
sion of NIS in children and adolescents, no significant
difference in NIS expression was found between benign and
malignant thyroid tumors [17]. Though no difference was
found between benign and malignant tumors, because the
overall recurrence risk was increased for tumors that had
undetectable NIS expression, the authors suggested that NIS
expression is a favorable prognostic indicator for DTC in
children and adolescents [17]. Although these results appear
to be in contrast with ours, in the former study, the expression
of NIS in the malignant tumor was compared to benign
lesions as a substitute of normal thyroid. In the present study
the expression of NIS in malignant tumors was compared
to its expression in normal thyroid. That is essential, as
previous studies have demonstrated that NIS expression was
lower in benign thyroid lesion compared to normal thyroid
tissue [28, 29]. Additionally, the authors studied patients
up to 21 years of age and only 2 cases under the age of
10. Hence, no comparison was made between children and
adolescents. Remarkably, NIS expression was not detected in
these patients under the age of 10 [17].
Another study suggested that the expression ofPDS,TPO,
andTSHRmRNA is higher in the pediatric group (5–21 years)
compared to adults (22–59 years). Nevertheless, among the 15
pediatric patients, only 3 cases were under 10 years of age, and
there was no specific information regarding the expression of
iodine-metabolizing genes in these patients [16].
As in our study the expression of NIS, PDS, and TSHR
was significantly different between children and adolescents;
the premise that the expression of iodine-metabolizing genes
is higher in all DTC from pediatric patients than in DTC
from adults might not be entirely true and seems too
oversimplified. The differences observed among children
and adolescents in the present study, at molecular level,
may explain the striking differences reported within the
pediatric group in terms of the clinical and pathological
features.
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To help to clarify the issue whether the level of expression
of iodide-metabolizing genes in children and adolescents
differs from that of adults, we next compared the expression
of NIS, PDS, and TSHR, which were found differentially
expressed between children and adolescents, with their
expression in adult population. We found that the expression
of NIS is comparable in tumors from children and adults.
Most significantly, the expression ofNISwas higher in tumor
from adolescents compared with children and adults. PDS
and TSHR expression were even lower in children than
in adolescents and adults. The higher expression of NIS,
PDS, and TSHR in adolescents suggested a greater degree
of differentiation of thyroid carcinomas in this age group.
The opposite is also true, that is, lower expression of this
thyroid-specific genes may indicate a lower grade of tumor
differentiation and, therefore, a more aggressive thyroid
tumor behavior in children.
There are some limitations to our study. First, it is limited
by the inherent biases of a retrospective analysis and therefore
the lack of a proper follow-up of the patients. Second, because
previously published guidelines about DTC management
were mainly addressed for adult DTC, the management
of pediatric DTC varies according to different medical
services. The patients enrolled in this study were followed
in three different hospitals with different criteria regarding
the surgical procedures, indications for RAI ablation and
dosing regimens, and follow-up protocol. The first guideline
specifically addressing the management of thyroid nodules
and DTC in children and adolescents was only recently
released [24]. For this reason, we decided not to analyze the
relationship between gene expression and response to RAI
treatment.
In conclusion, to the best of our knowledge, this is the first
study to report a differential thyroid-specific gene expression
profile within the pediatric group classified according to age.
Our data suggests that the biological behavior of tumors in
adolescents is different compared to tumors in patients under
the age of 10 and adults. The identification of age-related
differences may allow a subclassification of pediatric tumors
into genetic and clinical subtypes and will certainly add to
our ability to predict clinical outcomes and to develop future
treatment strategies tailored to the differences. Whether
genetic events might explain the phenotypic differences
warrants further investigation.
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